Optimal Selection of Data and Technology for Use Throughout the Orphan Medicinal Product Life Cycle
Wednesday, Nov 13 | 11:30am-12:15pm or 12:20pm-1:05pm (2 rotations) Erwin De Cock, Principal, Late Phase, Syneos Health
Optimizing the Transition from Translational Science to Clinical Development in Rare Disease
Wednesday, Nov 13 | 2:50pm-3:20pm Keith Ruark, Vice President, Syneos One
No Longer an Option – Evolving Market Demands a Fully Integrated Clinical and Commercial Approach for Orphan Drug Life Cycle Management Success
Thursday, Nov 14 | 2:10pm -2:40pm
Sharing case example insights for effective planning and execution for Rare and Orphan Medicinal Products
Leveraging the strategic and operational experience from our presenters to highlight what is unique and requires different practices in progressing assets in the area of rare diseases
Keith Ruark, Vice President, Syneos One
Maryna Kolochavina, Executive Director, Syneos One
